In 2023, the treatment of metastatic CRC continues to evolve with the utilization of newer systemic therapies (including targeted therapies such as anti‐EGFR monoclonal antibodies and immunotherapy) in conjunction with surgical resection after careful selection of patients with favorable biology in the setting of EHD. This evidence concerns the gene EGFR and colorectal carcinoma.